Biotechnology
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
* ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. * ESR1 mutations are present in up to 40% of ER+, HER2- advance...
2023-11-08 02:01
1764
Discovery Life Sciences Announces New CEO
Greg Herrema to Spearhead Next Phase of Global Biospecimen and Biomarker Company's Expansion HUNTSVILLE, Ala., Nov. 7, 2023 /PRNewswire/ -- Discovery Life Sciences, the Biospecimen and Biomarker Specialists, announced today the appointment ofGreg Herrema as its new chief executive officer. A lea...
2023-11-07 23:01
2078
Nuevocor presents pre-clinical data at ESGCT and AHA meetings
SINGAPORE, Nov. 7, 2023 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnologycompany focused on developing cardiac genetic medicines through a unique platform to understand the mechanobiological causes of disease, announced today a pair of presentations at two major meetings, the European ...
2023-11-07 22:00
1759
Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs
* Company's eTurna™ delivery platform ensures unprecedented precision, safety * In-vivo biodistribution of mRNA into dermal cells, tissues shows high transfection efficiency, gene expression * Data presented at ASDS Annual Meeting MOUNTAIN VIEW, Calif., Nov. 7, 2023 /PRNewswire/ -- Turn Biot...
2023-11-07 21:30
2724
Kexing Biopharm Attended CPHI Worldwide 2023
SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held inBarcelona, Spain. Kexing Biopharm exhibited more than ten kinds of high-quality medical products in the fields of tumor, autoimmune, anti-virus, etc., including Infliximab, Adalimumab, Bevacizumab,...
2023-11-07 20:09
1542
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)
HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus...
2023-11-07 20:00
1945
Xinhua Silk Road: E. China's Quanzhou: cheering up the power of technological innovation
BEIJING, Nov. 7, 2023 /PRNewswire/ -- Quanzhou, a city in east China's Fujian
Province, is not only an innovation-driven manufacturing city, but also a
creative hub that witnesses cutting-edge technologies continuously empower the
high-quality development of the private economy.
2023-11-07 16:39
2204
First Mover of Global Trade Index Based On Biome Molecule, Kwanyoung Park of AndKwan Natural Science
* Creating world-class innovation by redefining how international standards are established with eco-friendly bio materials and a system. * Patent registration for one-stop system from procurement of raw materials and golden time orders from all over the world to search for optimal routes for ...
2023-11-07 15:47
1841
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for the treatment of advanced malign...
2023-11-07 14:14
1413
87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held inIreland from...
2023-11-07 12:31
1516
2023 World Laureates Association Prize winners awarded in Shanghai
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- The five winners of the 2023 World Laureates Association Prize (WLA Prize) received their awards for their ground-breaking achievements in computer science or mathematics and life science or medicine onNov. 6 at the opening ceremony of the 6th WLA Forum held...
2023-11-07 09:49
515
Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil
-- Clover's seasonal influenza vaccine BLA submission has been completed in
Brazil, boosting Clover's global presence --
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2023-11-07 08:00
1764
Lerna Bio unveils its first-in-class solution to combat liver failure
SINGAPORE, CAMBRIDGE, Mass. and SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Lerna Biopharma Pte. Ltd (Lerna Bio) proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting inBoston organized by American Association for the Study of Liver Diseases (AA...
2023-11-06 22:00
1496
I-Mab Announces Participation at Jefferies and Piper Conferences in November
ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies...
2023-11-06 21:00
1447
Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications
Bispecific Antibody Candidate PM8002 demonstrated encouraging data at this year's ASCO Annual Meeting (abstract #2536 & #e13091) and ESMO Congress (abstract #1992P) BioNTech will hold exclusive licenses to develop and commercialize PM8002 globally excluding Greater China ZHUHAI, China, Nov. 6...
2023-11-06 20:00
2253
Novogene AMEA adopts Olink® Explore HT platform
SINGAPORE, Nov. 6, 2023 /PRNewswire/ -- Novogene Asia Pacific Middle East and Africa (AMEA), a leading provider of genomic services and solutions is pleased to announce the adoption of the Olink® Explore HT platform. The addition of Olink Explore HT enhances Novogene AMEA's capabilities and qual...
2023-11-06 18:00
1794
L'Oréal Announces North Asia Big Bang Beauty Tech Innovation Program Winners with Innovation Showcase at China International Import Expo
* "L'Oréal North Asia Big Bang Beauty Tech Innovation Program" (Big Bang) announced 17 innovative companies fromChina, Japan, Korea as 2023 Winners * First regional beauty tech innovation incubation exhibition unveiled at China International Import Expo featuring 16 overseas Big Bang finalist...
2023-11-06 15:00
2058
Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the safety, pharmacokinetics (PK), and pharmacodynamics (PD) data of ASC42, a novel farnesoid X receptor (FXR) agonist, in healthy subjects ha...
2023-11-06 12:20
1876
The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval
YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug...
2023-11-06 09:11
1494
XtalPi and CK Life Sciences Ink Agreement to Develop Cancer Molecular Diagnostic Models using AI and Biomarker Data
SHENZHEN, China, Nov. 6, 2023 /PRNewswire/ -- Today, XtalPi, a leading global technology company in combining artificial intelligence (AI) and robotics to drive the discovery of groundbreaking medicine and innovative materials, announced the signing of a new agreement with CK Life Sciences, a mem...
2023-11-06 09:00
2140
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
